What are you looking for?
top

KESIMPTA®▼ (ofatumumab) Sensoready Pen: self-injection video – healthcare professional instructions

KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.1

For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).1

KESIMPTA is intended for patient self-administration with initial guidance from a HCP. Please refer to the KESIMPTA Summary of Product Characteristics for further information.1

Watch this video to learn more about how to use KESIMPTA. This will help you teach your patients how to administer KESIMPTA with the Sensoready® pen after the initial dose.

KESIMPTA Sensoready Pen Self-injection video - Healthcare Professional Instructions VIDEO

Prescribing Information can be found at the top of the page.

HCP, healthcare professional; RMS, relapsing forms of MS.

Reference

  1. KESIMPTA (ofatumumab) Summary of Product Characteristics.

UK | January 2025 | 443398

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.